19 results on '"Gray, Nathanael S."'
Search Results
2. Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase.
- Author
-
Iacob, Roxana E., Jianming Zhang, Gray, Nathanael S., and Engen, John R.
- Subjects
- *
ADENOSINE triphosphate , *BINDING sites , *RETROVIRUSES , *DRUG resistance , *MASS spectrometry , *GENETIC mutation , *GENETICS , *ADENINE nucleotides , *SUPERINFECTION - Abstract
Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemogenic agents but drug resistance has become a significant clinical limitation. Recently, a compound that binds to the myristate pocket of Abl (GNF-5) was shown to act cooperatively with nilotinib, an ATP-competitive inhibitor to target the recalcitrant "T315I" gatekeeper mutant of Bcr-Abl. To uncover an explanation for how drug binding at a distance from the kinase active site could lead to inhibition and how inhibitors could combine their effects, hydrogen exchange mass spectrometry (HX MS) was employed to monitor conformational effects in the presence of both dasatinib, a clinically approved ATP-site inhibitor, and GNF-5. While dasatinib binding to wild type Abl clearly influenced Abl conformation, no binding was detected between dasatinib and T315I. GNF-5, however, elicited the same conformational changes in both wild type and T315I, including changes to dynamics within the ATP site located approximately 25 Å from the site of GNF-5 interaction. Simultaneous binding of dasatinib and GNF-5 to T315I caused conformational and/or dynamics changes in Abl such that effects of dasatinib on T315I were the same as when it bound to wild type Abl. These results provide strong biophysical evidence that allosteric interactions play a role in Abl kinase downregulation and that targeting sites outside the ATP binding site can provide an important pharmacological tool to overcome mutations that cause resistance to ATP-competitive inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. Activation of tyrosine kinases by mutation of the gatekeeper threonine.
- Author
-
Azam, Mohammad, Seelinger, Markus A., Gray, Nathanael S., Kuriyan, John, and Daley, George Q.
- Subjects
- *
GENETIC mutation , *PROTEIN-tyrosine kinases , *AMINO acids , *BLOOD proteins , *PROTEIN-protein interactions - Abstract
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells. Structural analysis reveals that a network of hydrophobic interactions—the hydrophobic spine—characteristic of the active kinase conformation is stabilized by the gatekeeper substitution. Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase. Furthermore, a small-molecule inhibitor that maximizes complementarity with the dismantled spine (compound 14) inhibits the gatekeeper mutation of BCR-ABL-T315I. These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
4. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
- Author
-
Jang, Jaebong, Son, Jieun, Park, Eunyoung, Kosaka, Takayuki, Saxon, Jamie A., De Clercq, Dries J. H., Choi, Hwan Geun, Tanizaki, Junko, Eck, Michael J., Jänne, Pasi A., and Gray, Nathanael S.
- Subjects
- *
EPIDERMAL growth factor receptors , *HER2 gene , *EXONS (Genetics) , *SMALL cell lung cancer , *GENETIC mutation - Abstract
Abstract: Exon 20 insertion (Ex20Ins) mutations are the third most prevalent epidermal growth factor receptor (EGFR) activating mutation and the most prevalent HER2 mutation in non‐small cell lung cancer (NSCLC). Novel therapeutics for the patients with Ex20Ins mutations are urgently needed, due to their poor responses to the currently approved EGFR and HER2 inhibitors. Here we report the discovery of highly potent and broadly effective EGFR and HER2 Ex20Ins mutant inhibitors. The co‐crystal structure of compound 1 b in complex with wild type EGFR clearly revealed an additional hydrophobic interaction of 4‐fluorobenzene ring within a deep hydrophobic pocket, which has not been widely exploited in the development of EGFR and HER2 inhibitors. As compared with afatinib, compound 1 a exhibited superior inhibition of proliferation and signaling pathways in Ba/F3 cells harboring either EGFR or HER2 Ex20Ins mutations, and in the EGFR P772_H773insPNP patient‐derived lung cancer cell line DFCI127. Our study identifies promising strategies for development of EGFR and HER2 Ex20Ins mutant inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
- Author
-
Weir, Mark C., Hellwig, Sabine, Tan, Li, Liu, Yao, Gray, Nathanael S., and Smithgall, Thomas E.
- Subjects
- *
ACUTE myeloid leukemia treatment , *PROTEIN-tyrosine kinases , *CELL lines , *GENETIC mutation , *APOPTOSIS - Abstract
Acute myelogenous leukemia (AML) is often associated with activating mutations in the receptor tyrosine kinase, Flt3, including internal tandem duplications (ITDs) within the regulatory juxtamembrane region. Previous studies have linked Flt3-ITD to the activation of the Fes protein tyrosine kinase in AML, and RNAi-knockdown studies suggest that Fes may be required for Flt3 function. In this study, we tested Fes inhibitors from three different chemical classes for their growth-suppressive activity against Flt3-ITD+ myeloid leukemia cell lines (MV4-11, MOLM-13 and MOLM-14) vs. myeloid cells with wild-type Flt3 (THP-1). All Fes inhibitors selectively inhibited the growth of Flt3-ITD+ AML cells, with IC50 values for diaminopyrimidine and pyrrolopyridine inhibitors ranging from 19 to 166 nM. In contrast, a pyrazolopyrimidine inhibitor was less potent in Flt3-ITD+ AML cells, with IC50 values in the 1.0 μM range. In vitro kinase assays showed that the most potent inhibitors of Flt3-ITD+ AML cell proliferation blocked both Fes and Flt3-ITD kinase activity, while the pyrazolopyrimidine was more selective for Fes vs. Flt3-ITD. All three inhibitors induced significant apoptosis in Flt3-ITD+ AML cells, with potency equivalent to or greater than the established Flt3-ITD inhibitor, tandutinib. Transformation of TF-1 cells with Flt3-ITD resulted in constitutive activation of endogenous Fes, and rendered the cells highly sensitive to all three Fes inhibitors with IC50 values in the 30–500 nM range. The pyrrolopyridine compound also induced apoptotic responses in patient-derived Flt3-ITD+ AML bone marrow cells but not in normal bone marrow mononuclear cells. These results demonstrate that Fes kinase activity contributes to Flt3-ITD signaling in AML, and suggests that dual inhibition of both Flt3 and Fes may provide a therapeutic advantage for the treatment of Flt3-ITD+ AML. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
- Author
-
Maxson, Julia E., Abel, Melissa L., Wang, Jinhua, Deng, Xianming, Reckel, Sina, Luty, Samuel B., Huahang Sun, Gorenstein, Julie, Hughes, Seamus B., Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K., Radich, Jerald, Hantschel, Oliver, Middleton, Richard E., Gray, Nathanael S., Druker, Brian J., and Tyner, Jeffrey W.
- Subjects
- *
LEUKEMIA diagnosis , *PROTEIN-tyrosine kinases , *GENETIC mutation , *DASATINIB , *DISEASE progression - Abstract
The amount of genomic information about leukemia cells currently far exceeds our overall understanding of the precise genetic events that ultimately drive disease development and progression. Effective implementation of personalized medicine will require tools to distinguish actionable genetic alterations within the complex genetic landscape of leukemia. In this study, we performed kinase inhibitor screens to predict functional gene targets in primary specimens from patients with acute myeloid leukemia and chronic myelomonocytic leukemia. Deep sequencing of the same patient specimens identified genetic alterations that were then integrated with the functionally important targets using the HitWalker algorithm to prioritize the mutant genes that most likely explain the observed drug sensitivity patterns. Through this process, we identified tyrosine kinase nonreceptor 2 (TNK2) point mutations that exhibited oncogenic capacity. Importantly, the integration of functional and genomic data using HitWalker allowed for prioritization of rare oncogenic mutations that may have been missed through genomic analysis alone. These mutations were sensitive to the multikinase inhibitor dasatinib, which antagonizes TNK2 kinase activity, as well as novel TNK2 inhibitors, XMD8-87 and XMD16-5, with greater target specificity. We also identified activating truncation mutations in other tumor types that were sensitive to XMD8-87 and XMD16-5, exemplifying the potential utility of these compounds across tumor types dependent on TNK2. Collectively, our findings highlight a more sensitive approach for identifying actionable genomic lesions that may be infrequently mutated or overlooked and provide a new method for the prioritization of candidate genetic mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.
- Author
-
Hatcher, John M., Bahcall, Magda, Hwan Geun Choi, Yang Gao, Taebo Sim, George, Rani, Jänne, Pasi A., and Gray, Nathanael S.
- Subjects
- *
NON-small-cell lung carcinoma , *CANCER treatment , *ANAPLASTIC lymphoma kinase , *GENETIC mutation , *DRUG development , *PATIENTS - Abstract
The treatment of patients with advanced non-small-cell lung cancer harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small-molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably develops through a variety of mechanisms, leading to relapse both systemically and in the central nervous system (CNS). This has motivated the development of "second-generation" ALK inhibitors, including alectinib and ceritinib, that overcome some of the mutations leading to resistance. However, most of the reported ALK inhibitors do not show inhibition of the G1202R mutant, which is one of the most common mutations. Herein, we report the development of a structural analogue of alectinib (JH-VIII-157-02) that is potent against the G1202R mutant as well as a variety of other frequently observed mutants. In addition, JH-VIII-157-02 is capable of penetrating the CNS of mice following oral dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
- Author
-
Moccia, Marialuisa, Liu, Qingsong, Guida, Teresa, Federico, Giorgia, Brescia, Annalisa, Zhao, Zheng, Choi, Hwan Geun, Deng, Xianming, Tan, Li, Wang, Jinhua, Billaud, Marc, Gray, Nathanael S., Carlomagno, Francesca, and Santoro, Massimo
- Subjects
- *
SMALL molecules , *PROTEIN-tyrosine kinase inhibitors , *GENETIC mutation , *ONCOGENES , *AUTOPHOSPHORYLATION - Abstract
Oncogenic mutation of the RET receptor tyrosine kinase is observed in several human malignancies. Here, we describe three novel type II RET tyrosine kinase inhibitors (TKI), ALW-II-41-27, XMD15-44 and HG-6-63-01, that inhibit the cellular activity of oncogenic RET mutants at two digit nanomolar concentration. These three compounds shared a 3-trifluoromethyl-4-methylpiperazinephenyl pharmacophore that stabilizes the ‘DFG-out’ inactive conformation of RET activation loop. They blocked RET-mediated signaling and proliferation with an IC50 in the nM range in fibroblasts transformed by the RET/C634R and RET/M918T oncogenes. They also inhibited autophosphorylation of several additional oncogenic RET-derived point mutants and chimeric oncogenes. At a concentration of 10 nM, ALW-II-41-27, XMD15-44 and HG-6-63-01 inhibited RET kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles; they also inhibited proliferation of cancer, but not non-tumoral Nthy-ori-3-1, thyroid cells, with an IC50 in the nM range. The three compounds were capable of inhibiting the ‘gatekeeper’ V804M mutant which confers substantial resistance to established RET inhibitors. In conclusion, we have identified a type II TKI scaffold, shared by ALW-II-41-27, XMD15-44 and HG-6-63-01, that may be used as novel lead for the development of novel agents for the treatment of cancers harboring oncogenic activation of RET. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma.
- Author
-
Liao, Rachel G., Joonil Jung, Tchaicha, Jeremy, Wilkerson, Matthew D., Sivachenko, Andrey, Beauchamp, Ellen M., Qingsong Liu, Pugh, Trevor J., Pedamallu, Chandra Sekhar, Hayes, D. Neil, Gray, Nathanael S., Getz, Gad, Kwok-Kin Wong, Haddad, Robert I., Meyerson, Matthew, and Hammerman, Peter S.
- Subjects
- *
SQUAMOUS cell carcinoma , *PAPILLARY carcinoma , *GENETIC mutation , *LUNG cancer , *CARCINOMA - Abstract
A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung SCC) has recently been reported, enabling the identification of genomic events that contribute to the oncogenesis of this disease. In lung SCC, one of the most frequently altered receptor tyrosine kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or mutation observed in all four family members. Here, we describe the oncogenic nature of mutations observed in FGFR2 and FGFR, each of which are observed in 3% of samples, for a mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that several of these mutations drive cellular transformation. Transformation can be reversed by small-molecule FGFR inhibitors currently being developed for clinical use. We also show that mutations in the extracellular domains of FGFR2 lead to constitutive FGFR dimerization. In addition, we report a patient with an FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib. These findings provide new insights into driving oncogenic events in a subset of lung squamous cancers, and recommend future clinical studies with FGFR inhibitors in patients with lung and head and neck SCC. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- Author
-
Liu, Qingsong, Sabnis, Yogesh, Zhao, Zheng, Zhang, Tinghu, Buhrlage, Sara J., Jones, Lyn H., and Gray, Nathanael S.
- Subjects
- *
PROTEIN kinases , *CELLULAR signal transduction , *GENETIC mutation , *PHARMACODYNAMICS , *KINASE inhibitors , *TARGETED drug delivery , *CYSTEINE - Abstract
Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential “kinase cysteinome” and discuss strategies for the efficient development of new covalent inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Development of ‘DFG-out’ inhibitors of gatekeeper mutant kinases
- Author
-
Choi, Hwan Geun, Zhang, Jianming, Weisberg, Ellen, Griffin, James D., Sim, Taebo, and Gray, Nathanael S.
- Subjects
- *
CHEMICAL inhibitors , *GENETIC mutation , *KINASES , *PYRIDINE , *PROTEIN-tyrosine kinase inhibitors , *MATHEMATICAL optimization - Abstract
Abstract: HG-7-85-01(22) and HG-7-86-01(26) are thiazolo[5,4-b]pyridine containing type II tyrosine kinase inhibitors with potent cellular activity against both wild-type and ‘gatekeeper’ mutant T315I- Bcr-Abl. Here we report on the ‘hybrid design’ concept and subsequent structure activity guided optimization efforts that resulted in the development of these inhibitors. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
12. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
- Author
-
Liu, Pixu, Cheng, Hailing, Santiago, Stephanie, Raeder, Maria, Zhang, Fan, Isabella, Adam, Yang, Janet, Semaan, Derek J, Chen, Changzhong, Fox, Edward A, Gray, Nathanael S, Monahan, John, Schlegel, Robert, Beroukhim, Rameen, Mills, Gordon B, and Zhao, Jean J
- Subjects
- *
MAMMARY gland tumors , *BREAST cancer treatment , *HUMAN genome , *GENE amplification , *FUNCTIONAL analysis , *GENETIC mutation , *ONCOGENES - Abstract
PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy, making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise of targeted therapy, resistance often develops, leading to treatment failure. To elucidate mechanisms of resistance to PI3K-targeted therapy, we constructed a mouse model of breast cancer conditionally expressing human PIK3CAH1047R. Notably, most PIK3CAH1047R-driven mammary tumors recurred after PIK3CAH1047R inactivation. Genomic analyses of recurrent tumors revealed multiple lesions, including focal amplification of Met or Myc (also known as c-Met and c-Myc, respectively). Whereas Met amplification led to tumor survival dependent on activation of endogenous PI3K, tumors with Myc amplification became independent of the PI3K pathway. Functional analyses showed that Myc contributed to oncogene independence and resistance to PI3K inhibition. Notably, PIK3CA mutations and c-MYC elevation co-occur in a substantial fraction of human breast tumors. Together, these data suggest that c-MYC elevation represents a potential mechanism by which tumors develop resistance to current PI3K-targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
13. Discovery of selective irreversible inhibitors for EGFR-T790M
- Author
-
Zhou, Wenjun, Ercan, Dalia, Jänne, Pasi A., and Gray, Nathanael S.
- Subjects
- *
BIOCHEMISTRY , *CHEMICAL inhibitors , *EPIDERMAL growth factor , *LUNG cancer , *GENETIC mutation , *CELL proliferation , *ADENOSINE triphosphate - Abstract
Abstract: Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M ‘gatekeeper’ resistance mutation relative to wild-type EGFR were discovered by library screening. A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. Broad spectrum alkynyl inhibitors of T315I Bcr-Abl
- Author
-
Deng, Xianming, Lim, Sang Min, Zhang, Jianming, and Gray, Nathanael S.
- Subjects
- *
CHEMICAL inhibitors , *ALKYNES , *PROTEIN kinases , *HYDROCARBONS , *GENETIC mutation - Abstract
Abstract: A series of alkyne-containing type II inhibitors with potent inhibitory activity of T315I Bcr-Abl has been identified. The most active compound 4 exhibits an EC50 of less than 1nM against wild-type Bcr-Abl and an EC50 of 10nM against T315I mutant but is broadly active against a number of other kinases. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
15. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
- Author
-
Wenjun Zhou, Ercan, Dalia, Liang Chen, Cai-Hong Yun, Li, Danan, Capelletti, Marzia, Cortot, Alexis B., Chirieac, Lucian, Iacob, Roxana E., Padera, Robert, Engen, John R., Kwok-Kin Wong, Eck, Michael J., Gray, Nathanael S., and Jänne, Pasi A.
- Subjects
- *
EPIDERMAL growth factor , *PROTEIN kinases , *CELL receptors , *GENETIC mutation , *LUNG cancer , *DRUG resistance in cancer cells , *QUINAZOLINE , *CANCER cells , *RESEARCH - Abstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
16. Conformational disturbance in Abl kinase upon mutation and deregulation.
- Author
-
Iacob, Roxana E., Pene-Dumitrescu, Teodora, Jianming Zhang, Gray, Nathanael S., Smithgall, Thomas E., and Engen, John R.
- Subjects
- *
GENETIC mutation , *GENETICS , *PROTEIN conformation , *PROTEIN folding , *LEUKEMIA diagnosis - Abstract
Protein dynamics are inextricably linked to protein function but there are few techniques that allow protein dynamics to be conveniently interrogated. For example, mutations and translocations give rise to aberrant proteins such as Bcr-Abl where changes in protein conformation and dynamics are believed to result in deregulated kinase activity that provides the oncogenic signal in chronic myelogeous leukemia. Although crystal structures of the down-regulated c-Abl kinase core have been reported, the conformational impact of mutations that render Abl resistant to small-molecule kinase inhibitors are largely unknown as is the allosteric interplay of the various regulatory elements of the protein. Hydrogen exchange mass spectrometry (HX MS) was used to compare the conformations of wild-type Abl with a nonmyristoylated form and with 3 clinically relevant imatinib resistance mutants (T3151, Y253H and E255V). A HX-resistant core localized to the interface between the SH2 and kinase domains, a region known to be important for maintaining the down-regulated state. Conformational differences upon demyristoylation were consistent with the SH2 domain moving to the top of the small lobe of the kinase domain as a function of activation. There were conformational changes in the T3151 mutant but, surprisingly, no major changes in conformation were detected in either the Y253H or the E255V mutants. Taken together, these results provide evidence that allosteric interactions and conformational changes play a major role in Abl kinase regulation in solution. Similar analyses could be performed on any protein to provide mechanistic details about conformational changes and protein function. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
17. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
- Author
-
George, Rani E., Sanda, Takaomi, Hanna, Megan, Fröhling, Stefan, II, William Luther, Zhang, Jianming, Ahn, Yebin, Zhou, Wenjun, London, Wendy B., McGrady, Patrick, Xue, Liquan, Zozulya, Sergey, Gregor, Vlad E., Webb, Thomas R., Gray, Nathanael S., Gilliland, D. Gary, Diller, Lisa, Greulich, Heidi, Morris, Stephan W., and Meyerson, Matthew
- Subjects
- *
GENETIC mutation , *NEUROBLASTOMA , *TUMORS in children , *NERVOUS system , *PROTEIN-tyrosine kinases , *GENE expression , *CELL lines , *NUCLEOTIDE sequence , *CELL-mediated cytotoxicity - Abstract
Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous system, accounts for approximately 15% of all deaths due to childhood cancer. High-risk neuroblastomas are rapidly progressive; even with intensive myeloablative chemotherapy, relapse is common and almost uniformly fatal. Here we report the detection of previously unknown mutations in the ALK gene, which encodes a receptor tyrosine kinase, in 8% of primary neuroblastomas. Five non-synonymous sequence variations were identified in the kinase domain of ALK, of which three were somatic and two were germ line. The most frequent mutation, F1174L, was also identified in three different neuroblastoma cell lines. ALK complementary DNAs encoding the F1174L and R1275Q variants, but not the wild-type ALK cDNA, transformed interleukin-3-dependent murine haematopoietic Ba/F3 cells to cytokine-independent growth. Ba/F3 cells expressing these mutations were sensitive to the small-molecule inhibitor of ALK, TAE684 (ref. 4). Furthermore, two human neuroblastoma cell lines harbouring the F1174L mutation were also sensitive to the inhibitor. Cytotoxicity was associated with increased amounts of apoptosis as measured by TdT-mediated dUTP nick end labelling (TUNEL). Short hairpin RNA (shRNA)-mediated knockdown of ALK expression in neuroblastoma cell lines with the F1174L mutation also resulted in apoptosis and impaired cell proliferation. Thus, activating alleles of the ALK receptor tyrosine kinase are present in primary neuroblastoma tumours and in established neuroblastoma cell lines, and confer sensitivity to ALK inhibition with small molecules, providing a molecular rationale for targeted therapy of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
18. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
- Author
-
Xianming Deng, Dzamko, Nicolas, Prescott, Alan, Davies, Paul, Qingsong Liu, Qingkai Yang, Jiing-Dwan Lee, Patricelli, Matthew P., Nomanbhoy, Tyzoon K., Alessi, Dario R., and Gray, Nathanael S.
- Subjects
- *
PARKINSON'S disease & genetics , *GENETIC mutation , *LEUCINE , *PHOSPHORYLATION , *PROTEOMICS , *INTRAPERITONEAL injections - Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson's disease. We employed a new, parallel, compound-centric approach to identify a potent and selective LRRK2 inhibitor, LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces dephosphorylation of Ser910 and Ser935 and accumulation of LRRK2 within aggregate structures. LRRK2-IN-1 will serve as a versatile tool to pharmacologically interrogate LRRK2 biology and study its role in Parkinson's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
- Author
-
Lu, Jia, Harrison, Rane A., Li, Lianbo, Zeng, Mei, Gondi, Sudershan, Scott, David, Gray, Nathanael S., Engen, John R., and Westover, Kenneth D.
- Subjects
- *
GENETIC mutation , *NON-small-cell lung carcinoma , *GUANINE nucleotide exchange factors , *X-ray crystallography , *DRUG design - Abstract
Summary KRAS G12C, the most common RAS mutation found in non-small-cell lung cancer, has been the subject of multiple recent covalent small-molecule inhibitor campaigns including efforts directed at the guanine nucleotide pocket and separate work focused on an inducible pocket adjacent to the switch motifs. Multiple conformations of switch II have been observed, suggesting that switch II pocket (SIIP) binders may be capable of engaging a range of KRAS conformations. Here we report the use of hydrogen/deuterium-exchange mass spectrometry (HDX MS) to discriminate between conformations of switch II induced by two chemical classes of SIIP binders. We investigated the structural basis for differences in HDX MS using X-ray crystallography and discovered a new SIIP configuration in response to binding of a quinazoline chemotype. These results have implications for structure-guided drug design targeting the RAS SIIP. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.